Patents Assigned to Chiron S.r.l.
-
Patent number: 7320875Abstract: HCV assays are described. The assays utilize a 24 kd protein capable of binding the E2 envelope protein of hepatitis C virus (HCV), or functionally equivalent variants or fragments of the 24 kd protein.Type: GrantFiled: March 9, 2006Date of Patent: January 22, 2008Assignee: Chiron S.r.l.Inventor: Sergio Abrignani
-
Patent number: 7179457Abstract: The invention provides a nodavirus RNA1 molecule modified to include a heterologous insertion which is downstream of its replicase ORF and, preferably, its B2 ORF. The insertion preferably comprises one or more protein-coding regions. The modified RNA1 may be packaged in a VLP, such as a papillomavirus VLP. The small size of nodavirus RNA1 makes it ideal for HPV packaging.Type: GrantFiled: March 26, 2001Date of Patent: February 20, 2007Assignee: Chiron S.r.l.Inventors: Giuliano Bensi, Alessio Zippo
-
Publication number: 20050281837Abstract: Immunologically active polypeptides with no or reduced toxicity useful for the preparation of an antipertussis vaccine. Method for the preparation of said polypeptides which comprises, cultivating a microorganisms transformed with a hybrid plasmid including the gene/s which codes for at least one of said polypeptides in a suitable medium and recovering the desired polypeptide from the cells or from the culture medium.Type: ApplicationFiled: January 29, 2004Publication date: December 22, 2005Applicant: Chiron S.r.l.Inventors: Mariagrazia Pizza, Antonella Bartoloni, Rino Rappuoli
-
Patent number: 6914131Abstract: The invention provides proteins from Neisseria meningitidis (strains A & B) and from Neisseria gonorrhoeae, including amino acid sequences, the corresponding nucleotide sequences, expression data, and serological data. The proteins are useful antigens for vaccines, immunogenic compositions, and/or diagnostics.Type: GrantFiled: April 30, 1999Date of Patent: July 5, 2005Assignee: Chiron S.r.l.Inventors: Vincenzo Scarlato, Vega Masignani, Rino Rappuoli, Mariagrazia Pizza, Guido Grandi
-
Patent number: 6900302Abstract: The invention relates to peptide, oligopeptide or polypeptide compounds that are capable of eliciting a protective immune response against the capsular polysaccharide of group B Streptococcus (GBS), particularly type III GBS. Such compounds are useful in the development of vaccines that are effective against diseases caused by these pathogens.Type: GrantFiled: November 7, 2003Date of Patent: May 31, 2005Assignee: Chiron S.r.l.Inventors: Giuseppe Teti, Luciano Polonelli
-
Patent number: 6855321Abstract: The invention relates to polyepitope carrier proteins that comprise at least five CD4+ T cell epitopes, for conjugation to capsular polysaccharides. The carrier proteins are use useful as components of vaccines that can elicit a T-cell dependent immune response. These vaccines arm particularly useful to confer protection against infection from encapsulated bacteria in infants between the ages of 3 months and about 2 years.Type: GrantFiled: April 27, 1999Date of Patent: February 15, 2005Assignee: Chiron S.r.l.Inventors: Rino Rappuoli, Guido Grandi
-
Patent number: 6841155Abstract: Methods for treating and/or protecting H. pylori infection are described. The methods utilize non-mucosal administration of an effective amount of one or more H. pylori antigens.Type: GrantFiled: April 30, 1999Date of Patent: January 11, 2005Assignee: Chiron S.r.l.Inventors: Guiseppe Del Giudice, Rino Rappuoli
-
Patent number: 6777538Abstract: A 24 kd protein capable of binding the E2 envelope protein of hepatitis C virus (HCV), and functionally equivalent variants or fragments of the 24 kd protein, are disclosed. Processes for production and purification of the 24 kd protein, and functionally equivalent variants or fragments thereof, are also disclosed.Type: GrantFiled: January 5, 2001Date of Patent: August 17, 2004Assignee: Chiron S.r.l.Inventor: Sergio Abrignani
-
Patent number: 6737233Abstract: A 24 kd percent capable of binding the E2 envelope protein of hepatitis C virus (HCV), and functionally equivalent variants or fragments of the 24 kd protein, are disclosed. Processes for production and purication of the 24 kd protein, and functionally equivalent variants or fragments thereof, are also disclosed.Type: GrantFiled: February 17, 1998Date of Patent: May 18, 2004Assignee: Chiron S.r.l.Inventor: Sergio Abrignani
-
Patent number: 6713072Abstract: Immunologically active polypeptides with no or reduced toxicity useful for the preparation of an antipertussis vaccine. Method for the preparation of said polypeptides which comprises, cultivating, a microorganism transformed with a hybrid plasmid including the gene/s which codes for at least one of said polypeptides in a suitable medium and recovering the desired polypeptide from the cells or from the culture medium.Type: GrantFiled: June 17, 1994Date of Patent: March 30, 2004Assignee: Chiron S.r.l.Inventors: Mariagrazia Pizza, Antonella Bartoloni, Rino Rappuoli
-
Patent number: 6676938Abstract: The invention relates to peptide, oligopeptide or polypeptide compounds that are capable of eliciting a protective immune response against the capsular polysaccharide of group B Streptococcus (GBS), particularly type III GBS. Such compounds are useful in the development of vaccines that are effective against diseases caused by these pathogens.Type: GrantFiled: May 17, 2001Date of Patent: January 13, 2004Assignee: Chiron S.r.L.Inventors: Giuseppe Teti, Luciano Polonelli
-
Patent number: 6649374Abstract: A new recombinant form of the plasmid-encoded protein pgp3 from C. trachomatis, serotype D, to be used in immunogenic compositions and in the preparation of immunogenic compositions was purified by ion exchange column chromatography and shown to be suitable for quantitative immunoassy on clinical samples in an ELISA format.Type: GrantFiled: January 23, 1998Date of Patent: November 18, 2003Assignee: Chiron S.r.l.Inventor: Giulio Ratti
-
Patent number: 6638513Abstract: The present invention pertains generally to Neisseria meningitidis serogroup B glycoconjugates. More particularly, the invention pertains to glycoconjugates formed from a Neisseria meningitidis serogroup B capsular oligosaccharide derivative (MenB OS derivative) in which sialic acid residue N-acetyl groups are replaced with N-acyl groups. The invention also pertains to vaccine formulations containing the glycoconjugates, methods of making the vaccine formulations, and methods of using the vaccine formulations to treat or prevent Neisseria meningitidis serogroup B or E. coli K1 disease in a mammalian subject.Type: GrantFiled: August 7, 1997Date of Patent: October 28, 2003Assignee: Chiron S.r.l.Inventor: Robert Seid